CoChat

Mood stabilizer psychopharmacology

Gould, Todd D., Chen, Guang, Manji, Husseini K. · 2002 · Clinical Neuroscience Research
Cited by 47

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1566-2772(02)00044-0

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 224

  1. Manji, 1999, Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications, J Clin Psychiatry, 60, 27
  2. Gould, 2002, Signaling networks in the pathophysiology and treatment of mood disorders, J Psychosom Res, 53, 687, 10.1016/S0022-3999(02)00426-9 · DOI
  3. Manji, 2000, Signaling: cellular insights into the pathophysiology of bipolar disorder, Biol Psychiatry, 48, 518, 10.1016/S0006-3223(00)00929-X · DOI · Paper page
  4. Waldmeier, 1987, Is there a common denominator for the antimanic effect of lithium and anticonvulsants?, Pharmacopsychiatry, 20, 37, 10.1055/s-2007-1017072 · DOI
  5. Chen, 1994, Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro, J Neurochem, 63, 2361, 10.1046/j.1471-4159.1994.63062361.x · DOI · Paper page
  6. Lenox, 1996, Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?, J Clin Psychiatry, 57, 23
  7. Manji, 1996, Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy, J Clin Psychiatry, 57, 34
  8. Jope, 1999, Anti-bipolar therapy: mechanism of action of lithium, Mol Psychiatry, 4, 117, 10.1038/sj.mp.4000494 · DOI · Paper page
  9. Williams, 2002, A common mechanism of action for three mood-stabilizing drugs, Nature, 417, 292, 10.1038/417292a · DOI · Paper page
  10. Hall, 2002, Valproate regulates GSK-3-mediated axonal remodeling and synapsin i clustering in developing neurons, Mol Cell Neurosci, 20, 257, 10.1006/mcne.2002.1117 · DOI · Paper page
  11. Amari, 1999, Comparison of fluorescence, (31)P NMR, and (7)Li NMR spectroscopic methods for investigating Li(+)/Mg(2+) competition for biomolecules, Anal Biochem, 272, 1, 10.1006/abio.1999.4169 · DOI
  12. Ryves, 2001, Lithium inhibits glycogen synthase kinase-3 by competition for magnesium, Biochem Biophys Res Commun, 280, 720, 10.1006/bbrc.2000.4169 · DOI · Paper page
  13. Davies, 2000, Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem J, 351, 95, 10.1042/0264-6021:3510095 · doi:10.1042/0264-6021:3510095 · Paper page
  14. York, 1995, Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure, Proc Natl Acad Sci USA, 92, 5149, 10.1073/pnas.92.11.5149 · DOI · Paper page
  15. Masuda, 2001, Phosphoglucomutase is an in vivo lithium target in yeast, J Biol Chem, 10, 10
  16. Klein, 1996, A molecular mechanism for the effect of lithium on development, Proc Natl Acad Sci USA, 93, 8455, 10.1073/pnas.93.16.8455 · DOI · Paper page
  17. Li, 2002, Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?, J Affect Disord, 69, 1, 10.1016/S0165-0327(00)00361-X · DOI
  18. Post, 1998, A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century, Neuropsychobiology, 38, 152, 10.1159/000026532 · DOI · Paper page
  19. Manji, 1992, G proteins: implications for psychiatry, Am J Psychiatry, 149, 746, 10.1176/ajp.149.6.746 · DOI · Paper page
  20. Casebolt, 1990, Alpha-1 adrenergic receptor binding and adrenergic-stimulated cyclic AMP production in rat cerebral cortex after chronic lithium treatment, J Neural Transm Gen Sect, 82, 197, 10.1007/BF01272762 · doi:10.1007/bf01272762
  21. Colin, 1991, Chronic lithium regulates the expression of adenylate cyclase and Gi- protein alpha subunit in rat cerebral cortex, Proc Natl Acad Sci USA, 88, 10634, 10.1073/pnas.88.23.10634 · DOI
  22. Jakobsen, 1998, Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain, Brain Res, 780, 46, 10.1016/S0006-8993(97)01181-5 · doi:10.1016/s0006-8993(97)01181-5
  23. Li, 1993, Effects of chronic lithium and carbamazepine treatment on G-protein subunit expression in rat cerebral cortex, Biol Psychiatry, 34, 162, 10.1016/0006-3223(93)90387-S · DOI
  24. Masana, 1992, In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain, J Neurochem, 59, 200, 10.1111/j.1471-4159.1992.tb08891.x · DOI
  25. Ebstein, 1986, The cyclic AMP second messenger system in man: the effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification, Prog Neuropsychopharmacol Biol Psychiatry, 10, 323, 10.1016/0278-5846(86)90011-4 · DOI
  26. Newman, 1992, Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: relation to serotonergic function, Psychopharmacology, 109, 231, 10.1007/BF02245505 · DOI
  27. Risby, 1991, The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects, Arch Gen Psychiatry, 48, 513, 10.1001/archpsyc.1991.01810300025004 · DOI
  28. Ebstein, 1987, Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: postreceptor modification of second messenger signal amplification, Psychiatry Res, 21, 221, 10.1016/0165-1781(87)90026-6 · doi:10.1016/0165-1781(87)90026-6
  29. Hsiao, 1992, Lithium administration modulates platelet Gi in humans, Life Sci, 50, 227, 10.1016/0024-3205(92)90276-U · DOI
  30. Lonati-Galligani, 1989, Effect of in vivo lithium treatment on (−)isoproterenol-stimulated cAMP accumulation in lymphocytes of healthy subjects and patients with affective psychoses, Pharmacopsychiatry, 22, 241, 10.1055/s-2007-1014607 · doi:10.1055/s-2007-1014607
  31. Wang, 1974, Effect of lithium on prostaglandin F1-stimulated adenylate cyclase activity of human platelets, Biochem Pharmacol, 23, 845, 10.1016/0006-2952(74)90215-9 · doi:10.1016/0006-2952(74)90215-9
  32. Garcia-Sevilla, 1986, Biochemical and functional evidence of supersensitive platelet alpha 2-adrenoceptors in major affective disorder. Effect of long-term lithium carbonate treatment, Arch Gen Psychiatry, 43, 51, 10.1001/archpsyc.1986.01800010053007 · DOI
  33. Kofman, 1998, Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin, Pharmacol Biochem Behav, 59, 191, 10.1016/S0091-3057(97)00410-3 · DOI
  34. Miki, 2001, Effects of subchronic lithium chloride treatment on G-protein subunits (Golf, Ggamma7) and adenylyl cyclase expressed specifically in the rat striatum, Eur J Pharmacol, 428, 303, 10.1016/S0014-2999(01)01343-7 · doi:10.1016/s0014-2999(01)01343-7
  35. Herve, 1993, G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase, J Neurosci, 13, 2237, 10.1523/JNEUROSCI.13-05-02237.1993 · DOI · Paper page
  36. Manji, 1995, Signal transduction pathways. Molecular targets for lithium's actions, Arch Gen Psychiatry, 52, 531, 10.1001/archpsyc.1995.03950190013003 · DOI · Paper page
  37. Mork, 1992, Effects of lithium on second messenger systems in the brain, Pharmacol Toxicol, 71, 4, 10.1111/j.1600-0773.1992.tb01624.x · DOI
  38. Chen, 2000, Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo, Bipolar Disord, 2, 217, 10.1034/j.1399-5618.2000.20303.x · DOI · Paper page
  39. Manji, 1995, Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment, Arch Gen Psychiatry, 52, 135, 10.1001/archpsyc.1995.03950140053007 · DOI
  40. Jope, 1999, A bimodal model of the mechanism of action of lithium, Mol Psychiatry, 4, 21, 10.1038/sj.mp.4000444 · DOI
  41. Wiborg, 1999, Region-selective effects of long-term lithium and carbamazepine administration on cyclic AMP levels in rat brain, Pharmacol Toxicol, 84, 88, 10.1111/j.1600-0773.1999.tb00879.x · DOI
  42. Manji, 2000, Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders, Curr Psychiatry Rep, 2, 479, 10.1007/s11920-000-0006-6 · DOI
  43. Ram, 1997, No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder, Arch Gen Psychiatry, 54, 44, 10.1001/archpsyc.1997.01830130048010 · doi:10.1001/archpsyc.1997.01830130048010
  44. Ambrosio, 2002, Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024, Neurochem Res, 27, 121, 10.1023/A:1014814924965 · DOI · Paper page
  45. Palmer, 1979, Interactions of antiepileptic drugs on adenylate cyclase and phosphodiesterases in rat and mouse cerebrum, Exp Neurol, 63, 322, 10.1016/0014-4886(79)90128-6 · doi:10.1016/0014-4886(79)90128-6
  46. Palmer, 1979, Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain, Epilepsia, 20, 95, 10.1111/j.1528-1157.1979.tb04782.x · doi:10.1111/j.1528-1157.1979.tb04782.x
  47. Elphick, 1990, Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948, Psychopharmacology, 100, 522, 10.1007/BF02244006 · doi:10.1007/bf02244006
  48. Van Calker, 1991, Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses, Eur J Pharmacol, 206, 285, 10.1016/0922-4106(91)90111-T · DOI
  49. Lewin, 1977, Cyclic AMP accumulation in cerebral cortical slices: effect of carbamazepine, phenobarbital, and phenytoin, Epilepsia, 18, 237, 10.1111/j.1528-1157.1977.tb04472.x · doi:10.1111/j.1528-1157.1977.tb04472.x
  50. Ferrendelli, 1979, Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain, Ann Neurol, 5, 533, 10.1002/ana.410050606 · doi:10.1002/ana.410050606
  51. Avissar, 1990, Carbamazepine and electroconvulsive shock attenuate beta-adrenoceptor and muscarinic cholinoceptor coupling to G proteins in rat cortex, Eur J Pharmacol, 189, 99, 10.1016/0922-4106(90)90235-P · DOI
  52. Chen, 1996, Attenuation of cyclic AMP production by carbamazepine, J Neurochem, 67, 2079, 10.1046/j.1471-4159.1996.67052079.x · DOI · Paper page
  53. Divish, 1991, Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action, J Neurosci Res, 28, 40, 10.1002/jnr.490280105 · doi:10.1002/jnr.490280105
  54. Ludvig, 1992, Dibutyryl cyclic AMP has epileptogenic potential in the hippocampus of freely behaving rats: a combined EEG-intracerebral microdialysis study, Neurosci Lett, 141, 187, 10.1016/0304-3940(92)90891-A · DOI
  55. Chen, 1996, Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells, Neuropsychopharmacology, 15, 271, 10.1016/0893-133X(95)00207-T · DOI
  56. Hudson, 1993, CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia, Synapse, 13, 278, 10.1002/syn.890130311 · DOI · Paper page
  57. Hallcher, 1980, The effects of lithium ion and other agents on the activity of myo- inositol-1-phosphatase from bovine brain, J Biol Chem, 255, 10896, 10.1016/S0021-9258(19)70391-3 · DOI · Paper page
  58. Naccarato, 1974, Biosynthesis of myo-inositol in rat mammary gland. Isolation and properties of the enzymes, Arch Biochem Biophys, 164, 194, 10.1016/0003-9861(74)90022-8 · DOI
  59. Majerus, 1992, Inositol phosphate biochemistry, Annu Rev Biochem, 61, 225, 10.1146/annurev.bi.61.070192.001301 · DOI · Paper page
  60. Berridge, 1989, Neural and developmental actions of lithium: a unifying hypothesis, Cell, 59, 411, 10.1016/0092-8674(89)90026-3 · DOI · Paper page
  61. Gani, 1993, Lithium and myo-inositol homeostasis, Biochim Biophys Acta, 1177, 253, 10.1016/0167-4889(93)90121-5 · DOI
  62. Allison, 1971, Reduced brain inositol in lithium-treated rats, Nat New Biol, 233, 267, 10.1038/newbio233267a0 · DOI · Paper page
  63. Moore, 1999, Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness, Am J Psychiatry, 156, 1902, 10.1176/ajp.156.12.1902 · DOI · Paper page
  64. Chen, 1999, Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants, Psychosom Med, 61, 599, 10.1097/00006842-199909000-00004 · DOI
  65. Fauroux, 1999, Inhibitors of inositol monophosphatase, J Enzyme Inhib, 14, 97, 10.3109/14756369909036548 · DOI
  66. Godfrey, 1989, Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex, J Neurochem, 52, 498, 10.1111/j.1471-4159.1989.tb09148.x · doi:10.1111/j.1471-4159.1989.tb09148.x
  67. Song, 1992, Chronic lithium treatment impairs phosphatidylinositol hydrolysis in membranes from rat brain regions, J Neurochem, 58, 2200, 10.1111/j.1471-4159.1992.tb10964.x · DOI
  68. Manji, 1994, Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C, Synapse, 16, 11, 10.1002/syn.890160103 · DOI · Paper page
  69. Jope, 1994, Lithium and brain signal transduction systems, Biochem Pharmacol, 47, 429, 10.1016/0006-2952(94)90172-4 · DOI · Paper page
  70. Vaden, 2001, Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis, J Biol Chem, 276, 15466, 10.1074/jbc.M004179200 · DOI
  71. Murray, 2000, Expression of yeast INM1 encoding inositol monophosphatase is regulated by inositol, carbon source and growth stage and is decreased by lithium and valproate, Mol Microbiol, 36, 651, 10.1046/j.1365-2958.2000.01886.x · DOI · Paper page
  72. van Calker, 2000, The high affinity inositol transport system – implications for the pathophysiology and treatment of bipolar disorder, Bipolar Disord, 2, 102, 10.1034/j.1399-5618.2000.020203.x · DOI
  73. Lubrich, 1999, Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs?, Neuropsychopharmacology, 21, 519, 10.1016/S0893-133X(99)00037-8 · DOI · Paper page
  74. Coyle, 2002, Getting balance: drugs for bipolar disorder share target, Nat Med, 8, 557, 10.1038/nm0602-557 · DOI
  75. Manji, 1999, Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness, Biol Psychiatry, 46, 1328, 10.1016/S0006-3223(99)00235-8 · DOI · Paper page
  76. Manji, 1996, Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol, Neuropsychopharmacology, 15, 370, 10.1016/0893-133X(95)00243-7 · DOI
  77. Manji, 1993, Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme, J Neurochem, 61, 2303, 10.1111/j.1471-4159.1993.tb07474.x · DOI · Paper page
  78. Li, 1995, Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells, J Neurochem, 65, 2500, 10.1046/j.1471-4159.1995.65062500.x · DOI
  79. Lenox, 1992, Chronic lithium administration alters a prominent PKC substrate in rat hippocampus, Brain Res, 570, 333, 10.1016/0006-8993(92)90598-4 · DOI
  80. Watson, 1996, Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation, J Neurochem, 67, 767, 10.1046/j.1471-4159.1996.67020767.x · DOI · Paper page
  81. Watson, 1998, Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers, J Pharmacol Exp Ther, 285, 307
  82. Post, 1992, Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness, Pharmacopsychiatry, 25, 41, 10.1055/s-2007-1014386 · DOI
  83. Steketee, 1991, Possible role for G-proteins in behavioral sensitization to cocaine, Brain Res, 545, 287, 10.1016/0006-8993(91)91299-G · DOI
  84. Steketee, 1991, Sensitization to psychostimulants and stress after injection of pertussis toxin into the A10 dopamine region, J Pharmacol Exp Ther, 259, 916
  85. Steketee, 1993, Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: behavioral and in vivo microdialysis studies, Neuropharmacology, 32, 1289, 10.1016/0028-3908(93)90023-V · DOI
  86. Steketee, 1994, Intra-A10 injection of H7 blocks the development of sensitization to cocaine, Neuroreport, 6, 69, 10.1097/00001756-199412300-00019 · DOI · Paper page
  87. Giambalvo, 1992, Protein kinase C and dopamine transport – 2. Effects of amphetamine in vitro, Neuropharmacology, 31, 1211, 10.1016/0028-3908(92)90049-U · DOI
  88. Giambalvo, 1992, Protein kinase C and dopamine transport – 1. Effects of amphetamine in vivo, Neuropharmacology, 31, 1201, 10.1016/0028-3908(92)90048-T · DOI
  89. Gnegy, 1993, Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine, Brain Res Mol Brain Res, 20, 289, 10.1016/0169-328X(93)90055-T · DOI
  90. Iwata, 1997, Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine, J Pharmacol Exp Ther, 283, 1445
  91. Iwata, 1997, Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes, Synapse, 26, 281, 10.1002/(SICI)1098-2396(199707)26:3<281::AID-SYN9>3.0.CO;2-3 · DOI · Paper page
  92. Daigen, 1991, Long-lasting enhancement of the membrane-associated protein kinase C activity in the hippocampal kindled rat, Jpn J Psychiatry Neurol, 45, 297
  93. Daigen, 1991, Long-lasting change in the membrane-associated protein kinase C activity in the hippocampal kindled rat, Brain Res, 545, 131, 10.1016/0006-8993(91)91278-9 · DOI
  94. Kantor, 1998, Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices, J Pharmacol Exp Ther, 284, 592
  95. Ur, 1992, Mania in association with hydrocortisone replacement for Addison's disease, Postgrad Med J, 68, 41, 10.1136/pgmj.68.795.41 · DOI
  96. Haskett, 1985, Diagnostic categorization of psychiatric disturbance in Cushing's syndrome, Am J Psychiatry, 142, 911, 10.1176/ajp.142.8.911 · DOI · Paper page
  97. Dwivedi, 1999, Administration of dexamethasone up-regulates protein kinase C activity and the expression of gamma and epsilon protein kinase C isozymes in the rat brain, J Neurochem, 72, 380, 10.1046/j.1471-4159.1999.0720380.x · DOI
  98. Nalepa, 1994, The responsiveness of cerebral cortical adrenergic receptors after chronic administration of atypical antidepressant mianserin, J Psychiatry Neurosci, 19, 120
  99. Nalepa, 1993, The antagonistic effect of separate and consecutive chronic treatment with imipramine and ECS on the inhibition of alpha 1-adrenoceptor activity by protein kinase C, Pol J Pharmacol, 45, 521
  100. Apparsundaram, 1998, Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins, J Pharmacol Exp Ther, 287, 744
  101. Apparsundaram, 1998, Acute regulation of norepinephrine transport: I. protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells, J Pharmacol Exp Ther, 287, 733
  102. Blakely, 1998, Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins, Biol Psychiatry, 44, 169, 10.1016/S0006-3223(98)00124-3 · DOI · Paper page
  103. Zhang, 1998, Expression and regulation of the human dopamine transporter in a neuronal cell line, Brain Res Mol Brain Res, 59, 66, 10.1016/S0169-328X(98)00138-7 · DOI
  104. Chen, 1997, Enhanced phosphorylation of the postsynaptic protein kinase C substrate RC3/neurogranin during long-term potentiation, Brain Res, 749, 181, 10.1016/S0006-8993(96)01159-6 · DOI
  105. Hahn, 1999, Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder, Bipolar Disord, 1, 81, 10.1034/j.1399-5618.1999.010204.x · DOI · Paper page
  106. Bebchuk, 2000, A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania, Arch Gen Psychiatry, 57, 95, 10.1001/archpsyc.57.1.95 · DOI
  107. Horgan, 1986, Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity, Biochem Pharmacol, 35, 4463, 10.1016/0006-2952(86)90764-1 · DOI
  108. O'Brian, 1988, Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue, Cancer Res, 48, 3626
  109. Cohen, 2001, The renaissance of GSK3, Nat Rev Mol Cell Biol, 2, 769, 10.1038/35096075 · DOI · Paper page
  110. Plyte, 1992, Glycogen synthase kinase-3: functions in oncogenesis and development, Biochim Biophys Acta, 1114, 147
  111. Woodgett, 2001, Judging a protein by more than its name: gsk-3, Sci STKE, 1, RE12
  112. Haugaard, 1974, Actions of lithium ions and insulin on glucose utilization, glycogen synthesis and glycogen synthase in the isolated rat diaphragm, Biochem Pharmacol, 23, 1675, 10.1016/0006-2952(74)90394-3 · DOI
  113. Cheng, 1983, ‘Insulin-like’ effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase, Mol Cell Biochem, 56, 183, 10.1007/BF00227219 · DOI
  114. Bosch, 1986, Effects of lithium ions on glycogen synthase and phosphorylase in rat hepatocytes, J Biol Chem, 261, 16927, 10.1016/S0021-9258(19)75978-X · DOI · Paper page
  115. Harwood, 2001, Regulation of GSK-3: a cellular multiprocessor, Cell, 105, 821, 10.1016/S0092-8674(01)00412-3 · DOI · Paper page
  116. Grimes, 2001, The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling, Prog Neurobiol, 65, 391, 10.1016/S0301-0082(01)00011-9 · DOI · Paper page
  117. Salinas, 1999, Lithium and synaptic plasticity, Bipolar Disord, 1, 87, 10.1034/j.1399-5618.1999.010205.x · DOI
  118. Gould, 2002, The Wnt signaling pathway in bipolar disorder, Neuroscientist, 8, 497, 10.1177/107385802237176 · DOI · Paper page
  119. Li, 2002, Glycogen synthase kinase 3-beta, mood stabilizers, and neuroprotection, Bipolar Disord, 4, 137, 10.1034/j.1399-5618.2002.40201.x · DOI · Paper page
  120. Manji, 2000, Neuroplasticity and cellular resilience in mood disorders, Mol Psychiatry, 5, 578, 10.1038/sj.mp.4000811 · DOI · Paper page
  121. Phiel, 2001, Molecular targets of lithium action, Annu Rev Pharmacol Toxicol, 41, 789, 10.1146/annurev.pharmtox.41.1.789 · DOI · Paper page
  122. Chen, 1999, The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3, J Neurochem, 72, 1327, 10.1046/j.1471-4159.2000.0721327.x · DOI · Paper page
  123. Grimes, 2001, CREB DNA binding activity is inhibited by glycogen synthase kinase-3beta and facilitated by lithium, J Neurochem, 78, 1, 10.1046/j.1471-4159.2001.00495.x · DOI · Paper page
  124. Axelrod, 1988, Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers, Trends Neurosci, 11, 117, 10.1016/0166-2236(88)90157-9 · DOI · Paper page
  125. Rapoport, 2001, In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling, J Mol Neurosci, 16, 243, 10.1385/JMN:16:2-3:243 · DOI · Paper page
  126. Axelrod, 1995, Phospholipase A2 and G proteins, Trends Neurosci, 18, 64, 10.1016/0166-2236(95)93873-V · doi:10.1016/0166-2236(95)93873-v
  127. Chang, 2001, Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers, J Neurochem, 77, 796, 10.1046/j.1471-4159.2001.00311.x · DOI · Paper page
  128. Chang, 1996, Lithium decreases turnover of arachidonate in several brain phospholipids, Neurosci Lett, 220, 171, 10.1016/S0304-3940(96)13264-X · DOI
  129. Rapoport, 2002, Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?, Arch Gen Psychiatry, 59, 592, 10.1001/archpsyc.59.7.592 · DOI · Paper page
  130. Chang, 1998, Chronic lithium treatment decreases brain phospholipase A2 activity, Neurochem Res, 23, 887, 10.1023/A:1022415113421 · DOI
  131. Rintala, 1999, 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain, Neuroreport, 10, 3887, 10.1097/00001756-199912160-00030 · DOI · Paper page
  132. Patapoutian, 2001, Trk receptors: mediators of neurotrophin action, Curr Opin Neurobiol, 11, 272, 10.1016/S0959-4388(00)00208-7 · DOI · Paper page
  133. Riccio, 1997, An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons, Science, 277, 1097, 10.1126/science.277.5329.1097 · DOI · Paper page
  134. Bonni, 1999, Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms, Science, 286, 1358, 10.1126/science.286.5443.1358 · DOI · Paper page
  135. Suzuki, 1995, ERK2-type mitogen-activated protein kinase (MAPK) and its substrates in postsynaptic density fractions from the rat brain, Neurosci Res, 22, 277, 10.1016/0168-0102(95)00902-6 · DOI
  136. Matsubara, 1996, Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions, J Biol Chem, 271, 21108, 10.1074/jbc.271.35.21108 · DOI · Paper page
  137. Kornhauser, 1997, A kinase to remember: dual roles for MAP kinase in long-term memory, Neuron, 18, 839, 10.1016/S0896-6273(00)80322-0 · DOI
  138. Fukunaga, 1998, Role of MAP kinase in neurons, Mol Neurobiol, 16, 79, 10.1007/BF02740604 · DOI · Paper page
  139. Robinson, 1998, A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation, Curr Biol, 8, 1141, 10.1016/S0960-9822(07)00485-X · DOI · Paper page
  140. Xu, 1997, Induction of mitogen-activated protein kinase phosphatase-1 during acute hypertension, Hypertension, 30, 106, 10.1161/01.HYP.30.1.106 · DOI
  141. Roberson, 1999, The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus, J Neurosci, 19, 4337, 10.1523/JNEUROSCI.19-11-04337.1999 · DOI · Paper page
  142. Roberson, 1996, A biochemist's view of long-term potentiation, Learn Mem, 3, 1, 10.1101/lm.3.1.1 · DOI · Paper page
  143. Chen, 1999, The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS, J Neurochem, 72, 879, 10.1046/j.1471-4159.1999.720879.x · DOI · Paper page
  144. Manji, 1999, Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?, Biol Psychiatry, 46, 929, 10.1016/S0006-3223(99)00165-1 · DOI · Paper page
  145. Chen, 1999, Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity, J Biol Chem, 274, 6039, 10.1074/jbc.274.10.6039 · DOI · Paper page
  146. Fukumoto, 2001, Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain, Psychopharmacology (Berl), 158, 100, 10.1007/s002130100871 · DOI · Paper page
  147. Chen, 2002, Evidence for the Involvement of the ERK MAP kinase signaling cascade in mood modulation, Biol Psychiatry, 51, 3685
  148. Yuan, 2001, The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth, J Biol Chem, 276, 31674, 10.1074/jbc.M104309200 · DOI · Paper page
  149. Chuang, 2002, Neuroprotective effects of lithium in cultured cells and animal model of diseases, Bipolar Disord, 4, 129, 10.1034/j.1399-5618.2002.01179.x · DOI · Paper page
  150. Jope, 2002, Mood stabilizers, glycogen synthase kinase-3b and cell survival, Mol Psychiatry, 7, S35, 10.1038/sj.mp.4001017 · DOI
  151. Inouye, 1995, Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum, J Radiat Res (Tokyo), 36, 203, 10.1269/jrr.36.203 · doi:10.1269/jrr.36.203
  152. Grignon, 1996, Tyrosine kinase inhibitors and cycloheximide inhibit Li+ protection of cerebellar granule neurons switched to non-depolarizing medium, Eur J Pharmacol., 315, 111, 10.1016/S0014-2999(96)00591-2 · DOI
  153. Li, R., Shen Y, El-Mallakh RS. Lithium protects against ouabain-induced cell death. Lithium 1994;5(4):211-216.
  154. Volonte, 1993, Lithium chloride promotes short-term survival of PC12 cells after serum and NGF deprivation, Lithium, 4, 211
  155. D'Mello, 1994, Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons, Exp Cell Res, 211, 332, 10.1006/excr.1994.1095 · DOI
  156. Manji, 2000, Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness, Biol Psychiatry, 48, 740, 10.1016/S0006-3223(00)00979-3 · DOI · Paper page
  157. Rajkowska, 2000, Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells, Biol Psychiatry, 48, 766, 10.1016/S0006-3223(00)00950-1 · DOI · Paper page
  158. Rajkowska, 2002, Cell pathology in bipolar disorder, Bipolar Disord, 4, 105, 10.1034/j.1399-5618.2002.01149.x · DOI · Paper page
  159. Harrison, 2002, The neuropathology of primary mood disorder, Brain, 125, 1428, 10.1093/brain/awf149 · DOI · Paper page
  160. Wei, 2001, Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease, Neuroscience, 106, 603, 10.1016/S0306-4522(01)00311-6 · DOI · Paper page
  161. Nonaka, 1998, Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats, Neuroreport, 9, 2081, 10.1097/00001756-199806220-00031 · DOI · Paper page
  162. Bruno, 1995, Antidegenerative effects of Mg(2+)-valproate in cultured cerebellar neurons, Funct Neurol, 10, 121
  163. Mark, 1995, Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology, Neurobiol Aging, 16, 187, 10.1016/0197-4580(94)00150-2 · DOI
  164. Mora, 1999, Different mechanisms of protection against apoptosis by valproate and Li+, Eur J Biochem, 266, 886, 10.1046/j.1432-1327.1999.00919.x · DOI · Paper page
  165. Hashimoto, 2002, Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation, J Neurochem, 80, 589, 10.1046/j.0022-3042.2001.00728.x · DOI · Paper page
  166. Bijur, 2000, Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium, J Biol Chem, 275, 7583, 10.1074/jbc.275.11.7583 · DOI · Paper page
  167. Inestrosa, 2000, Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity, Acta Neurol Scand Suppl, 176, 53, 10.1034/j.1600-0404.2000.00308.x · DOI · Paper page
  168. Dong, 1994, Effects of carbamazepine on hypoxic and ischemic brain damage in mice [in Chinese], Zhongguo Yao Li Xue Bao, 15, 257
  169. Moore, 2000, Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects?, Biol Psychiatry, 48, 1, 10.1016/S0006-3223(00)00252-3 · DOI · Paper page
  170. Soares, 2002, Can brain-imaging studies provide a ‘mood stabilizer signature’?, Mol Psychiatry, 71, S64, 10.1038/sj.mp.4001020 · DOI
  171. Cade, 1949, Lithium salts in the treatment of psychotic excitement, Med J Austr, 2, 349, 10.5694/j.1326-5377.1949.tb36912.x · DOI · Paper page
  172. Lenox, 2000, Overview of the mechanism of action of lithium in the brain: fifty-year update, J Clin Psychiatry, 61, 5
  173. Shaldubina, 2001, The mechanism of lithium action: state of the art, ten years later, Prog Neuropsychopharmacol Biol Psychiatry, 25, 855, 10.1016/S0278-5846(01)00154-3 · DOI
  174. Nakashima, 1976, Size-dependent allosteric effects of monovalent cations on rabbit liver fructose-1,6-bisphosphatase, J Biol Chem, 251, 4315, 10.1016/S0021-9258(17)33298-2 · doi:10.1016/s0021-9258(17)33298-2
  175. Nordenberg, 1982, Effects of lithium on the activities of phosphofructokinase and phosphoglucomutase and on glucose-1,6-diphosphate levels in rat muscles, brain and liver, Biochem Pharmacol, 31, 1025, 10.1016/0006-2952(82)90338-0 · DOI
  176. Yenush, 2000, A novel target of lithium therapy, FEBS Lett, 467, 321, 10.1016/S0014-5793(00)01183-2 · DOI
  177. Rhyu, 1984, Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase. Phosphorus NMR studies, Biochemistry, 23, 252, 10.1021/bi00297a013 · doi:10.1021/bi00297a013
  178. Ray, 1978, The binding of lithium and of anionic metabolites to phosphoglucomutase, Biochim Biophys Acta, 522, 434, 10.1016/0005-2744(78)90076-1 · DOI
  179. Martinez, 2002, Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation, Med Res Rev, 22, 373, 10.1002/med.10011 · DOI · Paper page
  180. Emrich, 1980, Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders, Arch Psychiatr Nervenkr, 229, 1, 10.1007/BF00343800 · DOI · Paper page
  181. Lambert, 1987, Use of valpromide in psychiatric therapeutics [in French], Encephale, 13, 367
  182. Bowden, 1994, Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group, J Am Med Assoc, 271, 918, 10.1001/jama.1994.03510360044034 · DOI · Paper page
  183. Pope, 1991, Valproate in the treatment of acute mania. A placebo-controlled study, Arch Gen Psychiatry, 48, 62, 10.1001/archpsyc.1991.01810250064008 · DOI · Paper page
  184. Lemperiere, 2001, Brief history of the development of valproate in bipolar disorders [in French], Encephale, 27, 365
  185. Lambert, 1992, Comparative study of valpromide versus lithium in the treatment of affective disorders, Nervure, 5, 57
  186. Macdonald, 1995, Antiepileptic drug mechanisms of action, Epilepsia, 36, S2, 10.1111/j.1528-1157.1995.tb05996.x · DOI · Paper page
  187. Johannessen, 2000, Mechanisms of action of valproate: a commentary, Neurochem Int, 37, 103, 10.1016/S0197-0186(00)00013-9 · DOI · Paper page
  188. van der Laan, 1979, Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase, J Neurochem, 32, 1769, 10.1111/j.1471-4159.1979.tb02290.x · doi:10.1111/j.1471-4159.1979.tb02290.x
  189. Anlezark, 1976, Proceedings: gamma-Aminobutyric acid metabolism and the anticonvulsant action of ethanolamine-o-sulphate and di-n-propylacetate, Br J Pharmacol, 56, 383
  190. Sawaya, 1975, Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA, Epilepsia, 16, 649, 10.1111/j.1528-1157.1975.tb04747.x · doi:10.1111/j.1528-1157.1975.tb04747.x
  191. Whittle, 1978, Effects of the anticonvulsant sodium valproate on gamma-aminobutyrate and aldehyde metabolism in ox brain, J Neurochem, 31, 1453, 10.1111/j.1471-4159.1978.tb06572.x · doi:10.1111/j.1471-4159.1978.tb06572.x
  192. Balazs, 1970, The operation of the gamma-aminobutyrate bypath of the tricarboxylic acid cycle in brain tissue in vitro, Biochem J, 116, 445, 10.1042/bj1160445 · DOI · Paper page
  193. Leiderman, 1991, Effect of valproate on human cerebral glucose metabolism, Epilepsia, 32, 417, 10.1111/j.1528-1157.1991.tb04671.x · DOI · Paper page
  194. Gaillard, 1996, Effect of valproate on cerebral metabolism and blood flow: an 18F-2-deoxyglucose and 15O water positron emission tomography study, Epilepsia, 37, 515, 10.1111/j.1528-1157.1996.tb00602.x · DOI · Paper page
  195. Godin, 1969, Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism, J Neurochem, 16, 869, 10.1111/j.1471-4159.1969.tb08975.x · DOI · Paper page
  196. Loscher, 1993, Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain, Neurochem Res, 18, 485, 10.1007/BF00967253 · DOI
  197. Gottlicher, 2001, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, EMBO J, 20, 6969, 10.1093/emboj/20.24.6969 · DOI · Paper page
  198. Loscher, 1985, Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice, Neuropharmacology, 24, 427, 10.1016/0028-3908(85)90028-0 · DOI
  199. Radatz, 1998, Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid, Epilepsy Res, 30, 41, 10.1016/S0920-1211(97)00095-8 · doi:10.1016/s0920-1211(97)00095-8
  200. Lampen, 1999, New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta), Toxicol Appl Pharmacol, 160, 238, 10.1006/taap.1999.8770 · DOI

200 of 224 shown

Cited by

See all 47

Metadata

Authors
Gould, T. D., Chen, G., & Manji, H. K.
Venue
Clinical Neuroscience Research
Publisher
Elsevier BV
Published
2002-12
Volume
2
Issue
3-4
Pages
193-212
ISSN
1566-2772
Cited by
47
References
9
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mood stabilizer psychopharmacology. https://app.cochat.ai/papers/10.1016/s1566-2772(02)00044-0
The paper
Gould, T. D., Chen, G., & Manji, H. K. (2002). Mood stabilizer psychopharmacology. Clinical Neuroscience Research. https://doi.org/10.1016/s1566-2772(02)00044-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.